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Abstract
Background: Gram-negative bacteria cause most nosocomial respiratory infections. At the
University of Cumhuriyet, we examined 328 respiratory isolates of Enterobacteriaceae and
Acinetobacter baumanii organisms in Sivas, Turkey over 3 years. We used disk diffusion or
standardized microdilution to test the isolates against 18 antibiotics.
Results: We cultured organisms from sputum (54%), tracheal aspirate (25%), and bronchial lavage
fluid (21%). The most common organisms were Klebsiella spp (35%), A. baumanii (27%), and
Escherichia coli (15%). Imipenem was the most active agent, inhibiting 90% of Enterobacteriaceae and
A. baumanii organisms. We considered approximately 12% of Klebsiella pneumoniae and 21% of E.
coli isolates to be possible producers of extended-spectrum beta-lactamase. K. pneumoniae isolates
of the extended-spectrum beta-lactamase phenotype were more resistant to imipenem,
ciprofloxacin, and tetracycline in our study than they are in other regions of the world.
Conclusions: Our results suggest that imipenem resistance in our region is growing.
Background
Nosocomial bacterial pneumonia is frequently pol-
ymicrobial, with gram-negative bacilli predominating [1].
Because delays in antimicrobial treatment can lead to
adverse outcomes, the choice of empirical therapy is vital.
Many effective antimicrobial agents are available, but the
treatment of nosocomial pneumonia remains challeng-
ing. We recently reported the antibiotic-resistance patterns
of respiratory isolates of Pseudomonas aeruginosa in our
region [2]. The current study investigates the distribution
and drug resistance of other gram-negative bacteria in the
respiratory secretions of hospitalized patients.
Results
Table 1 and Table 2 present the antibiotic susceptibility
patterns of our isolates. The most common organisms
were Klebsiella spp (35%), A. baumanii (27%), and E. coli
(15%). We also isolated rare organisms such as Stenotro-
phomonas maltophilia, Burkholderia spp, and Hafnia alvei.
All studied Enterobacteriaceae (except Enterobacter spp)
were far more susceptible to ticarcillin-clavulanate than to
ticarcillin alone, which suggests that the primary mecha-
nism of resistance in these organisms is β-lactamase
production.
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Klebsiella spp were generally more susceptible to the tested
antimicrobials than were Enterobacter spp, Serratia spp, or
E. coli. The overall resistance rates to the third-generation
cephalosporins (cefotaxime, ceftazidime, and ceftriaxone)
were as follows: Klebsiella spp, 10%–19%; Serratia spp,
16%–33%; and Enterobacter spp, 22%–45%. Serratia spp
were less resistant to third-generation cephalosporins
than Enterobacter spp. E. coli isolates resistant to piperacil-
lin, gentamicin, and the fluoroquinolones accounted for
only 4% of all E. coli isolates. Imipenem was the most
active agent against our isolates.
After imipenem, ciprofloxacin, and the aminoglycosides,
tetracycline was the most active agent against A. baumanii.
Tobramycin was more effective against A. baumanii than
against Enterobacteriaceae. Tobramycin and imipenem
were the most active agents against both gentamicin- and
ciprofloxacin-resistant A. baumanii (Table 3).
Table 1: Susceptibility rates (percentages) of Enterobacteriaceae and Acinetobacter baumanii between January 1999 and November 1999 
(Disk diffusion method).
Antibiotics Klebsiella spp (n: 28) E.coli (n: 18) Proteus spp. (n: 10) Enterobacter spp (n: 10) A. baumanii (n: 7) Serratia spp. (n: 6)
Ampicillin - 33.3 - - - -
Amoxicillin/clav. 7.1 33.3 - - - -
Aztreonam 42.9 44.4 50.0 60.0 - 33.3
Piperacillin 32.1 27.8 50.0 30.0 - 33.3
Cefazolin 64.3 66.7 50.0 10.0 14.3 -
Cefuroxime 46.4 66.7 40.0 40.0 - -
Cefotaxime 67.9 72.2 90.0 100.0 - 66.7
Ceftazidime 71.4 72.2 70.0 90.0 14.3 50.0
Ceftriaxone 71.4 88.9 90.0 90.0 - 50.0
Amikacin 92.9 100.0 100.0 100.0 28.6 100.0
Gentamicin 82.1 100.0 80.0 90.0 85.7 100.0
Tobramycin 10.7 16.6 - 41.7 14.3 33.3
Ciprofloxacin 92.9 88.9 90.0 70.0 42.9 100.0
İmipenem 100.0 100.0 80.0 100.0 100.0 100.0
Tetracycline - 22.2 20.0 20.0 - 16.7
Cotrimoxazole 64.3 55.6 70.0 100.0 14.3 100.0
Table 2: Susceptibility rates of Enterobacteriaceae and Acinetobacter baumanii between November 1999 and January 2002 
(Microdilution technique).
Antibiotics Klebsiella spp (n: 86) A. baumanii (n: 83) E.coli (n: 30) Enterobacter spp (n: 24) Proteus spp. (n: 13) Serratia spp. (n: 13)
MIC50/90 Susc. % MIC50/90 Susc. % MIC50/90 Susc. % MIC50/90 Susc. % MIC50/90 Susc. % MIC50/90 Susc. %
Ampicillin 8/>16 10.5 16/>16 7.2 8/>16 10.0 8/>16 4.2 8/>16 15.4 8/>16 -
Amoxicillin/
clav.
4/>16 77.9 16/>16 7.2 4/>16 13.3 8/>16 4.2 4/>16 84.6 8/>16 -
Aztreonam 2/>16 73.3 8/>16 6.0 2/>16 66.6 2/>16 45.8 2/>16 92.3 2/16 84.6
Piperacillin 16/>64 60.5 16/128 39.7 16/128 30.0 16/128 41.7 16/>64 84.6 16/128 61.5
Ticarcillin 32/>64 25.6 16/128 7.2 16/128 26.7 32/128 54.2 32/>64 53.8 32/128 38.5
Ticarcillin/clav. 16/128 60.5 16/128 9.6 16/128 40.0 16/128 58.3 16/>64 92.3 16/128 61.5
Cefazolin 8/>16 77.9 16/>16 1.2 8/>16 46.7 8/>16 8.3 8/>16 69.2 8/>16 -
Cefuroxime 8/>16 88.4 16/>16 3.6 8/>16 46.7 8/>16 12.5 8/>16 76.9 8/>16 -
Cefotaxime 8/64 96.5 16/64 9.6 16/64 73.3 8/64 58.3 8/64 100.0 8/32 84.6
Ceftazidime 1/>16 84.9 4/>16 42.2 1/>16 66.7 1/32 37.5 1/>16 92.3 1/>16 76.9
Ceftriaxone 16/>32 90.7 16/64 12.0 16/>32 73.3 8/>32 50.0 16/>32 100.0 8/32 84.6
Amikacin 16/>32 93.0 16/>32 54.2 16/>32 93.3 8/>32 100.0 16/>32 100.0 8/>32 92.3
Gentamicin 4/16 89.5 4/16 65.0 4/>8 90.0 4/>8 95.8 4/>8 69.2 4/>8 84.6
Tobramycin 4/16 84.9 4/16 91.5 4/>8 93.3 4/>8 41.7 4/>8 84.6 4/>8 76.9
Ciprofloxacin 1/>2 89.5 1/>2 66.2 1/>2 66.6 1/>2 100.0 1/>2 100.0 1/>2 92.3
İmipenem 2/>8 95.3 4/>8 79.5 2/>8 96.6 2/>8 79.2 2/>8 100.0 2/>8 69.2
Tetracycline 4/>8 81.4 4/>8 56.6 4/>8 63.3 4/>8 79.2 4/>8 15.4 4/>8 15.4
Cotrimoxazole 1/>2 81.4 1/>2 22.9 1/>2 53.3 1/>2 75.0 1/>2 23.1 1/>2 69.2Page 2 of 5
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(20.8%) and 11 K. pneumoniae isolates (12.2%). All K.
pneumoniae and E. coli isolates with the ESBL phenotype
were resistant to tetracycline. Regarding K. pneumoniae iso-
lates, 2 were susceptible to tobramycin, 3 to gentamicin,
and 4 to ciprofloxacin, but 8 were susceptible to amikacin
and imipenem. Regarding E. coli isolates, 4 were suscepti-
ble to tobramycin, 7 to gentamicin, 5 to ciprofloxacin,
and 8 to amikacin, but all were susceptible to imipenem.
Discussion
Contrary to the findings of the Turkish antimicrobial
resistance study group [3], our Klebsiella isolates were
more susceptible to third-generation cephalosporins
(42.6% vs. 81.6% for ceftazidime; 65.8% vs. 85.7% for
cefotaxime), aztreonam (44.0% vs. 65.6%), and ticarcil-
lin-clavulanate (37.0% vs. 60.3%). Klebsiella spp were
81.6% susceptible to ceftazidime in our study; these rates
are 96.6% in North America [4], 86.7% in China [5],
80.5% in Korea [6], 69.4% in Latin America [7], and
51.9% in India [8].
Although the isolation of Acinetobacter spp in respiratory
specimens may reflect colonization and not necessarily
infection [9], the most common site of nosocomial Aci-
netobacter infection is the lower respiratory tract, especially
in mechanically ventilated patients [10]. Acinetobacter spp
were the second most frequent gram-negative bacilli iso-
lated from patients with pneumonia in Latin America [7].
In our survey, all compounds tested showed decreased
activity among the A. baumanii isolates. Susceptibility to
imipenem was >95% in Canada [11], India [8], and China
[5]; susceptibility was 80.5% in our study and 55.5% in
another study from Turkey [12]. The high prevalence of
respiratory tract infections due to multiresistant A. bauma-
nii will stimulate the use of carbapenems and possibly
increase carbapenem resistance in our region.
Only 75% of our E. coli isolates were susceptible to cipro-
floxacin. However, this rate was greater in Europe (95.2%)
[13], North America (93.3%) [4], and Latin America
(93.9%) [7]. E. coli's susceptibility to ceftazidime was
>95% in Europe [13], North America [4], China [5], and
Korea [6] but only 84.8% in Latin America [7], 69.6% in
our study, and 42.1% in India [8]. Imipenem, the most
active compound, inhibited 97.8% of our E. coli isolates.
Conversely, E. coli strains were not resistant to imipenem
in Europe [13], Latin America [7], India [8], China [5], or
Korea [6].
Enterobacter spp showed high rates of resistance to broad-
spectrum penicillins with or without β-lactamase
inhibitors (41.7% resistance to ticarcillin-clavulanate)
and third-generation cephalosporins (45.2% resistance to
ceftazidime). The high rates of ceftazidime resistance
among Enterobacter spp suggests a high prevalence of sta-
bly derepressed AmpC cephalosporinase-producing
strains. Interestingly, resistance to third-generation cepha-
losporins, aztreonam, and ticarcillin-clavulanate was
higher in our study (28.1%–48.0%) than with the Turkish
antimicrobial resistance study group (13.3%–38.3%) [3].
In their study, no Enterobacter or Serratia isolates were
resistant to imipenem. In our study, however, the rates of
susceptibility to imipenem were 86.2% for Enterobacter
Table 3: Susceptibility (numbers) of imipenem-, gentamicin-, and ciprofloxacin-resistant Acinetobacter baumanii.
All isolates (n: 90) Gentamicin-resistant (n: 30) Imipenem-resistant (n: 18) Ciprofloxacin-resistant (n: 32)
Ampicillin 6 2 - -
Amoxicillin/clavulanate 6 3 - -
Aztreonam 5 1 1 -
Piperacillin 33 4 1 9
Ticarcillin 6 2 - 1
Ticarcillin/clavulanate 8 5 - 1
Cefazolin 2 1 - -
Cefuroxime 3 - 1 -
Cefotaxime 8 1 1 -
Ceftazidime 36 5 6 7
Ceftriaxone 10 1 1 -
Amikacin 47 2 6 13
Gentamicin 60 - 11 25
Tobramycin 58 24 17 28
Ciprofloxacin 58 21 11 -
İmipenem 72 25 - 26
Tetracycline 47 17 10 6
Cotrimoxazole 20 10 5 6Page 3 of 5
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for these two species was >95% in other parts of the world
[7-10,13]. Moreover, Serratia spp were at least 95% sus-
ceptible to ceftazidime in the United States [14], Canada
[11], India [8], China [5], and Korea [6].
From 1997 to 1999, ESBL detection rates in K. pneumoniae
isolates were 45.4% in Latin America, 24.6% in the West-
ern Pacific, 22.6% in Europe, 7.6% in the United States,
and 4.9% in Canada [15]; this rate was 12.2% in our sur-
vey, but the other study from Turkey reported a rate of
60.5% [3]. During this same period, ESBL detection rates
in E. coli isolates were 8.5% in Latin America, 7.9% in the
Western Pacific, 5.3% in Europe, 4.2% in Canada, and
3.3% in the United States [15]; this rate was 20.8% in our
study. The presence of the ESBL phenotype in E. coli iso-
lates decreased susceptibility to the aminoglycosides, tet-
racycline, and ciprofloxacin but not imipenem, suggesting
the presence of other resistance genes in ESBL-encoding
plasmids. Despite the high percentage of ESBL production
in E. coli isolates, antibiotics remained reasonably effec-
tive with these isolates. Imipenem was active against all
ESBL-producing E. coli isolates. E. coli remained 30.0%
resistant to gentamicin; this resistance rate was 75.9% in
the Western Pacific, 57.8% in Latin America, 25.7% in
Europe, and 21.1% in the United States [15].
Only 0.5%–0.7% of ESBL-producing K. pneumoniae iso-
lates were resistant to imipenem in the United States,
Latin America, the Western Pacific region, and Canada
[15]. Our rate (27.2%) was very high in comparison. This
finding may be due to our low number of isolates or our
lack of a confirmation test for the ESBL phenotype. Resist-
ance to tetracycline among ESBL-producing K. pneumoniae
strains was 61.1% in Canada, 55.1% in the Western
Pacific, 52.0% in Latin America, 49.5% in Europe, and
44.4% in the United States [15], but this rate was 100% in
our study. Resistance to ciprofloxacin among ESBL-pro-
ducing K. pneumoniae strains was 44.2% in the Western
Pacific, 34.6% in the United States, 24.3% in Europe,
23.1% in Latin America, 22.2% in Canada, and 63.6% in
our study.
We found only one imipenem-resistant E. coli isolate. It
was resistant to ampicillin, ticarcillin, and piperacillin but
susceptible to ceftazidime, ceftriaxone, and aztreonam.
This profile suggests an oxacillinase with carbapenemase
properties. This finding is interesting because class D
enzymes have been found only in Acinetobacter spp [16].
Two imipenem-resistant Klebsiella spp were resistant to all
β-lactams, including aztreonam. These species were prob-
ably expressed a metallo-β-lactamase with additional
mechanisms (efflux, cephalosporinase hyperproduction)
[16].
The absence of a confirmation test for the ESBL phenotype
limits the impact of our results. On the other hand, it is
known that supplemented media (blood) can alter the
zone diameters for several agents and bacterial species.
Despite these limitations, our data can be used for local
therapeutic choices.
Conclusions
We previously presented the antibiotic susceptibility pat-
terns of 249 respiratory isolates of P. aeruginosa during the
same period [2]. When combined with our current data,
these results show that, in our region, ceftazidime can still
be used for managing respiratory infections due to gram-
negative aerobic bacteria in combination with aminogly-
cosides. It appears that increasing imipenem resistance
may cause serious therapeutic problems in future.
Methods
We collected our data from 01/01/1999 to 01/01/2002 at
the microbiology laboratory of the University of Cum-
huriyet. We processed the data to eliminate duplicate reg-
istrations. We excluded any isolates collected within 7
days when they came from the same specimen source of
the same patient. We initially identified the isolates using
such routine methods as colonial/microscopic morphol-
ogy and enzymatic characteristics. We confirmed species
identification with API-bioMerieux products. We retro-
spectively analyzed antibiotic susceptibility patterns in
238 respiratory isolates of Enterobacteriaceae members
and 90 respiratory isolates of A. baumanii. We accepted all
consecutive isolates because we did not attempt to distin-
guish actual pathogens from colonizing strains. Specimen
types consisted of sputum (54.2%), transtracheal/
endotracheal aspirates (24.6%), and bronchial lavage
fluid (21.2%). We cultured sputum samples that showed
no oral contamination in the presence of sputum puru-
lence or a suspected lower respiratory infection.
We confirmed susceptibility to 18 antimicrobial agents
using disk diffusion according to the National Committee
for Clinical Laboratory Standards (NCCLS) guidelines
[17], except insofar as we supplemented Mueller-Hinton
agar with 5% defibrinated blood. We aerobically
incubated the inoculated plates at 35°C and evaluated
them after 24 h. For quality control of the disk diffusion
tests, we used E. coli ATCC 25922 and Staphylococcus
aureus ATCC 25923 strains. The disks (Oxoid) contained
the following antimicrobials: ampicillin (10 µg), ampicil-
lin/sulbactam (20 µg), piperacillin (100 µg), aztreonam
(30 µg), cefazolin (30 µg), cefuroxime (30 µg), cefotaxime
(30 µg), ceftriaxone (30 µg), ceftazidime (30 µg), ami-
kacin (30 µg), gentamicin (10 µg), tobramycin (10 µg),
ciprofloxacin (5 µg), imipenem (10 µg), tetracycline (30
µg), and cotrimoxazole (25 µg). Until November 1999,
our microbiology laboratory based susceptibility rates onPage 4 of 5
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disk zone sizes; thereafter, we used a coordinating labora-
tory to determine the minimal inhibitory concentrations
(MICs) of these 18 antimicrobial agents, accomplished
with a standardized microdilution technique (Sceptor
System, Becton Dickinson Microbiology System). We
used this system to determine MICs for all strains. We
used the NCCLS criteria to identify possible extended-
spectrum β-lactamase (ESBL)-producing strains of Kleb-
siella spp and E. coli when MICs were increased (2 mg/mL)
with ceftazidime and/or ceftriaxone and/or aztreonam
[18], but we lacked a test to confirm the ESBL phenotype.
We classified our results into two categories. We labeled
strains deemed susceptible by the disk diffusion method
or microdilution technique as susceptible. We labeled all
resistant and intermediate isolates as resistant. We divided
the number of resistant isolates by the total number of
isolates that had undergone susceptibility testing.
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